Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients.

Schaefer, Anne; Sachpekidis, Christos; Diella, Francesca; Doerks, Anja; Kratz, Anne-Sophie; Meisel, Christian; Jackson, David B; Soldatos, Theodoros G

Schaefer, Anne; Sachpekidis, Christos; Diella, Francesca; Doerks, Anja; Kratz, Anne-Sophie; Meisel, Christian; Jackson, David B; Soldatos, Theodoros G.

Afiliación

Schaefer A; Molecular Health GmbH, 69115 Heidelberg, Germany.
Sachpekidis C; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Diella F; Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
Doerks A; Molecular Health GmbH, 69115 Heidelberg, Germany.
Kratz AS; Molecular Health GmbH, 69115 Heidelberg, Germany.
Meisel C; Molecular Health GmbH, 69115 Heidelberg, Germany.
Jackson DB; Molecular Health GmbH, 69115 Heidelberg, Germany.
Soldatos TG; Molecular Health GmbH, 69115 Heidelberg, Germany.

Cancers (Basel) ; 12(4)2020 Apr 19.

Article en En | MEDLINE | ID: mdl-32325840

Palabras clave

FDA's Adverse Event Reporting System (FAERS); Pembrolizumab; VigiBase; adverse events; data mining; immune checkpoint inhibitors; melanoma; pharmacoepidemiology

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2020 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google